






































Multimodal analysis of drug transporter expression
in gastrointestinal tissue
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Objectives: Drug transporters affect antiretroviral therapy (ART) tissue disposition, but
quantitative measures of drug transporter protein expression across preclinical species
are not available. Our objective was to use proteomics to obtain absolute transporter
concentrations and assess agreement with corresponding gene and immunometric
protein data.
Design: In order to make interspecies comparisons, two humanized mouse [hu-HSC-
Rag (n¼41); bone marrow-liver-thymus (n¼13)] and one primate [rhesus macaque
(nonhuman primate, n¼12)] models were dosed to steady state with combination ART.
Ileum and rectum were collected at necropsy and snap frozen for analysis.
Methods: Tissues were analyzed for gene (quantitative PCR) and protein [liquid
chromatography-mass spectrometry (LC-MS) proteomics and western blot] expression
and localization (immunohistochemistry) of ART efflux and uptake transporters. Drug
concentrations were measured by LC-MS/MS. Multivariable regression was used to
determine the ability of transporter data to predict tissue ART penetration.
Results: Analytical methods did not agree, with different trends observed for gene and
protein expression. For example, quantitative PCR analysis showed a two-fold increase
in permeability glycoprotein expression in nonhuman primates versus mice; however,
proteomics showed a 200-fold difference in the opposite direction. Proteomics results
were supported by immunohistochemistry staining showing extensive efflux transporter
localization on the luminal surface of these tissues. ART tissue concentration was
variable between species, and multivariable regression showed poor predictive power
of transporter data.
Conclusion: Lack of agreement between analytical techniques suggests that resources
should be focused on generating downstream measures of protein expression to predict
drug exposure. Taken together, these data inform the use of preclinical models for
studying ART distribution and the design of targeted therapies for HIV eradication.
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Introduction
Despite the efficacy of combination antiretroviral therapy
(cART), early studies of cART-treated patients showed
persistent infection and rapid rebound viremia after drug
removal even from patients with undetectable viral loads,
necessitating lifelong therapy [1,2]. There is evidence that
HIV replication can persist within certain anatomic sites,
or tissue reservoirs, including the central nervous system,
lymphatic system, gut-associated lymphoid tissue
(GALT), and genital tract [3–5]. HIV persistence in
GALT is of particular concern, given that ongoing
replication at this site may result in prolong immune
dysregulation and delayed T-cell recovery even after
cART initiation, suggesting that inadequate ART
exposure may propagate HIV replication at this site
[6]. It has been shown by our group and others that ART
tissue penetration is highly variable between anatomic
sites and between ARTwithin a single tissue [7]. Further,
Fletcher et al. [8] demonstrated that higher tissue ART
concentrations were significantly associated with faster
HIV decay within the lymph nodes and gastrointestinal
tract. More recently, we have shown our ability to image
ART within harvested tissue slices, and found hetero-
geneous efavirenz (EFV) distribution in several anatomic
sites, particularly in the gastrointestinal tract [9]. Further
investigation into what factors govern these distribution
patterns is critical for understanding how to increase ART
exposure in GALT.
Drug transporters play an important role in the
disposition of many antiretrovirals and are extensively
expressed throughout the gut. Several groups, including
our own, have published studies evaluating the expression
and localization of drug transporters in tissues relevant for
HIV prevention [10,11] and, more recently, cure [12].
However, there has been no consensus in the field on the
optimal way to measure transporter expression. There is
little agreement between publications with regard to what
is being measured (i.e. gene vs. protein expression), and
there has been no assessment of the extent of agreement
between techniques [e.g. quantitative PCR (qPCR) vs.
western blot vs. immunohistochemistry (IHC)]. Further,
although proteomics-based methods have been used to
obtain absolute concentrations of specific proteins
including drug transporters [13,14], this technology has
not been compared against other methods in the context
of HIV infection. A comprehensive evaluation of
transporter expression and localization using multiple
techniques within the same study is greatly needed to
inform the field as to the best way to measure transporter
expression for their effect on ART concentration
in tissues.
In addition to methodological considerations, another
important variable to address is expression differences
between species. Animal models are commonly used to
study HIV infection, and any evaluation of the tissue
exposure of a new or existing ART must first be
performed in animals before moving into humans.
Whereas there are some data showing similarities in
ARTexposure between humans and animals [15], there is
a paucity of data comparing important variables for drug
distribution between animal models or between animals
and humans. Further, the effect of HIV infection on these
variables has not been elucidated. Identification and
quantitation of these differences, if they exist, will help to
prevent the inappropriate extrapolation of data from one
species to another, determine whether pharmacokinetic
information should be obtained during infection, and
streamline the drug development process.
In the present study, we perform a comprehensive
evaluation of drug transporter expression and localization
in two tissues of the gastrointestinal tract [4,16] using
multiple methodologies and three animal models from
two species. These data help identify important variables
for ARTexposure into tissue reservoirs, while at the same
time identifying the best way to measure drug transporter
expression. Finally, the generation of novel interspecies
data can help determine the applicability of animal
models to future ART development.
Materials and methods
Animal dosing and tissue collection
Three commonly used animal models were employed in
this study: the hu-HSC-Rag (n¼ 41) and bone marrow-
liver-thymus (BLT; n¼ 13) humanized mouse models,
and a nonhuman primate (NHP) model (n¼ 12).
Detailed dosing and infection information for all animals
can be found in the Supplementary Methods (http://
links.lww.com/QAD/B114). Doses for all drugs were
chosen based on commonly used treatment doses for HIV
infection in these models [15,17–20]. ART dosing
combinations were chosen based on the limited resources
available (i.e. NHPs) or on toxicity (e.g. EFV in BLT
mice). Two animals from each mouse model were not
dosed with ART and used as controls. Ileum and rectum
were collected at necropsy and snap frozen. All animal
experiments were performed in accordance with locally
approved Institutional Animal Care and Use Committee
protocols.
Gene expression analysis
Transporter gene expression (including human genes in
the humanized mouse samples) was analyzed by qPCR on
five efflux and four uptake transporters (Supplementary
Table 2, http://links.lww.com/QAD/B114), chosen
based on their relevance to ART disposition and
expression in the gastrointestinal tract [21]. Approxi-
mately 30 mg of tissue was homogenized in lysis buffer
using a Precellys Tissue Homogenizer (Bertin Technol-
ogies, Montigny-le-Bretonneux, France) and RNA was
extracted using a Qiagen RNAeasy Mini Kit (Qiagen,
Valencia, California, USA) as per manufacturer’s proto-
col. Also, 200 ng of RNA was reverse transcribed to
cDNA using the VILO Superscript cDNA Synthesis Kit
(Thermo Fisher, Waltham, Massachusetts, USA). Forty
cycles of qPCR were performed using Taqman primers
and probes (Supplementary Table 3, http://links.lww.-
com/QAD/B114) on a QuantStudio6 (Life Technol-
ogies, Waltham, Massachusetts, USA). Expression for all
transporters was normalized to the housekeeping gene
GAPDH using the 2-DCT method [22]. All samples were
run in triplicate, and variability within and between
reaction plates was low, with standard deviation (SD) less
than 0.2 CT.
Protein expression analysis
Protein used for western blot and liquid chromatography-
mass spectrometry (LC-MS) proteomics was isolated
using a modified version of an extraction method
optimized for proteomics as described previously
[23,24] and listed in detail in Supplementary Methods
(http://links.lww.com/QAD/B114). For western blot,
up to 10 mg of protein was loaded onto a 4–12%
electrophoresis gel (NuPage) and run for 110 min at
180 V. Transfer onto a polyvinylidene fluoride membrane
(NuPage) occurred over 90 min at 30 V. After blocking in
5% milk, membranes were incubated in primary antibody
for 1–3 h (Supplementary Table 4, http://links.lww.-
com/QAD/B114), then rinsed and incubated in sec-
ondary antibody for 1–2 h. Development occurred using
Clarity ECL reagents (Bio-Rad, Hercules, California,
USA) with a Chemi-Doc XRSþ Imager (Bio-Rad), and
densitometry relative to GAPDH was calculated using
ImageLab 5.2.1 (Bio-Rad). A combination of 15 mg each
of mouse brain extract, liver extract, and T98G cell lysate
was used as the positive control sample. For proteomics
analysis, up to 50 mg of protein underwent 18-h digestion
with 1pmol stabile isotope labeled (SIL) peptide standards
added (Supplementary Methods, http://links.lww.com/
QAD/B114) and was analyzed using a nanoACQUITY
system (Waters, Milford, Massachusetts, USA) coupled to
a QTRAP 5500 mass spectrometer (AB SCIEX,
Framingham, Massachusetts, USA) equipped with
Nanospray III source.
Immunohistochemistry
Tissues were sliced frozen at 10 mm thickness using a
cryostat (Leica Biosystems, Wetzlar, Germany) and thaw
mounted onto glass microscope slides. The frozen slides
were then stained with primary antibody (Supplementary
Table 3, http://links.lww.com/QAD/B114) for 15–
60 min followed by pH antigen retrieval (Leica Biosys-
tems). DAB (3,3’-diaminobenzidine) was used as a
substrate-chromagen for detection. All staining was
performed on a Leica Bond automated tissue stainer
(Leica Biosystems). Samples were visually evaluated for
transporter localization.
Statistical analysis
Comparisons between dosing cohorts, species, and
anatomic compartments were made using one-way
Kruskal–Wallis analysis of variance (ANOVA) on ranks.
Pearson’s correlation on log-transformed values was used
to determine the relationship between gene expression
and protein expression by each method for all combined
samples. To determine which transporter evaluation
method best predicted tissue ART penetration, univariate
regression analysis was performed using log-transformed
TPR values versus transporter expression results [as
measured by qPCR, western blot, quantitative targeted
absolute proteomics (QTAP), or IHC]. Those variables
achieving P< 0.05 in the univariate analysis were
included in a multivariable analysis to identify combi-
nations of variables significantly predicting TPR.
Descriptive statistics and between-group comparisons
were conducted using SigmaPlot 13.0 (Systat Software
Inc., San Jose, California, USA), and the univariate and
multivariable analyses were performed using SAS 9.3
(Cary, North Carolina, USA); P< 0.05 was considered
significant.
Results
Drug transporter gene expression
Comparisons between individual dosing cohorts for the
ileum and rectum showed no significant differences
between individual dosing cohorts, so these data were
combined to assess total gene expression. Pooled ileum
and rectum data from mice and macaques were compared
in Fig. 1. ABCB1 demonstrated a significant two-fold
increase in expression in macaques vs. mice (Fig. 1c),
whereas the other efflux transporters did not differ
significantly between species or tissue site. The uptake
transporters SLCO2A1 and SLC29A1 did not differ
between species. SLC22A2 was increased 0.5-fold in
mouse rectum versus ileum and was not detected at all in
macaque tissues (Fig. 1h). SLC22A3 was 2–3 logs more
highly expressed in mice ileum and rectum compared to
macaques (Fig. 1i).
Interspecies comparison of transporter protein
expression by western blot analysis
Figure 2 shows western blot results, with representative
blots shown in Fig. 2a–d. Densitometry data from all
mouse samples are shown in Fig. 2e and Fig. 3f,
which demonstrates large variability in protein expression
(0.2–100-fold GAPDH). Densitometry analysis of
individual mouse dosing cohorts did not indicate
significant differences between dosing cohorts or mouse
models. Figure 2 (g–j) compares mouse and NHP western
blot data. Relative protein expression trends were similar
between mice and macaques for multidrug resistance-
associated proteins 1 (MRP1) and 2 (MRP2) and breast
cancer resistance protein (BCRP). Interestingly, multidrug
resistance protein (MDR1) protein expression showed a
significant opposite trend compared to the ABCB1 gene
expression between species, with relative MDR1 protein
expression 1–2 logs higher than macaques in both the
ileum and rectum.
Interspecies comparison of transporter protein
expression by targeted quantitative proteomic
analysis
No significant differences were observed between
infected and uninfected animals or individual dosing
cohorts, so ileac and rectal QTAP data from all cohorts of
mice were combined and compared to those generated in
macaques (Fig. 3). MDR1 protein concentrations were
2 logs higher in the mouse ileum compared to macaques
(Fig. 3c), which is similar to the western blot analysis, and
contrary to observed ABCB1 gene expression. Further,
the significant differences in ABCC4 expression between
infected and uninfected mice were not replicated in the
protein analysis (Fig. 3d). The 3-log increase in SLC22A3
gene expression in mice over macaques was also not
replicated here (Fig. 3h). There were also several
significant differences in protein concentrations that
were not present in the qPCR analysis. SLCO2A1, for
example, was not significantly different between species
in gene expression; however, a significant increase in
OATP2A1 concentrations was observed in macaques
compared to mice (Fig. 3f).
Transporter localization in the ileum and rectum
Immunohistochemistry staining revealed distinct local-
ization of several drug transporters within the gastroin-
testinal tract (representative images in Supplementary
Fig. 2, http://links.lww.com/QAD/B114). In both the
ileum and rectum, MDR1 was found to localize on the
luminal surface of the gut mucosa in tissues from all three
animal models, and was readily expressed. Conversely,
MRP2 was not detected in any tissue from any animal,
though protein was sporadically detected with western
blot (Fig. 2) and QTAP (Fig. 3). BCRP was detected in
the ileum of both mouse models, and showed a similar
localization profile to MDR1. MRP1 localized to the
luminal surface in a similar fashion to MDR1 and was
expressed in all tissues. MRP4 was localized to the lamina
propria in all three species, with extensive positive
staining on the basolateral surface of mucosal cells.
Fig. 1. Multispecies comparison of transporter gene expression. Gene expression is represented as fold change of GAPDH for
uninfected (white) and infected (gray) animals from multiple dosing cohorts. Data shown are median and range. SLC22A2 was
observed in mouse tissues only. NHP¼nonhuman primate; () represents P<0.05.
Human transporter expression in humanized
mice
Supplementary Fig. 3 (http://links.lww.com/QAD/
B114) provides an overview of human transporter gene
expression as it relates to mouse gene expression in the
same tissues. We observed human gene expression for
more than half of the transporters evaluated. Expression
was in general 1–5 logs lower than the mouse genes, with
the notable exceptions of ABCB1 and ABCC4, which in
some samples were 2 logs higher than mouse expression.
An analysis of the relationship between the extent of
humanization and the amount of human transporter
gene expression did not show any significant relationship
(data not shown). Western blot analysis using human-
specific antibodies showed detectable bands for MDR1
only, which had fold-GAPDH values that were within
50% of mouse protein expression (data not shown).
However, QTAP analysis using human-specific SILs
did not detect any MDR1 in any humanized mouse
sample, nor did it detect human protein from any other
transporter (data not shown). To demonstrate that
earlier interspecies comparisons for ABCB1 and ABCC4
were not confounded by a lack of accounting for human
gene expression, we re-analyzed these data after
accounting for the contribution of human gene
expression of these transporters (Supplementary Fig. 3c
and d, http://links.lww.com/QAD/B114). Our ABCB1
results were not significantly altered; however, median
ABCC4 expression in the uninfected mouse rectum
greatly increased (P< 0.01) over corresponding data
in NHPs.
Methodology comparison for drug transporter
evaluations
Correlation matrices were generated for the four efflux
transporters evaluated by all three methods using
combined data from all animals (Fig. 4). Correlation
coefficients were low for most comparisons, showcasing
the lack of agreement between techniques. Comparison
of QTAP and western for MDR1and MRP1 showed the
strongest correlation and reached statistical significance
(P< 0.01); however, the large amount of variability in
the data does not provide convincing evidence that these
methods are in high agreement. Correlation between
qPCR and QTAP for the uptake transporters was also
poor, with no comparison reaching statistical significance
(data not shown).
Results from the multivariable analysis are shown in
Table 1. The ability to predict ART tissue penetration
(shown in Supplementary Table 5, http://links.lww.
com/QAD/B114) was generally low, with R2 values
ranging from 0.09 [tenofovir (TFV) TPR predicted by
qPCR] to 0.51 [emtricitabine (FTC) TPR predicted by
western blot]. qPCR data were able to generate
significantly predictive regression models for each drug
Fig. 2. Transporter protein expression humanized mice ileum and rectum. (a–e) Representative western blots for four efflux
transporters from each animal cohort. The symbol ‘þ’ represents the positive control sample. Samples with no detectable GAPDH
were not included in subsequent analyses. Densitometry data from each blot was quantified for each transporter in mice (f) ileum
and (g) rectum, where protein expression is represented as a fold change over GAPDH for uninfected (light gray) and infected (dark
gray) animals. Zero values were imputed at 104 (dashed line) for graphing purposes. (h–k) Comparison of all mice and macaques
is shown, where data are median and range. Solid line represents equal protein expression to GAPDH; () represents P< 0.05.
evaluated, though the resulting R2 values tended to be
lower than those generated by western blot. QTAP data
generated significant models for TFV, FTC, and
raltegravir (RAL) only, and R2 values were lower than
qPCR or western blot in every case. There was little
agreement between methods regarding which specific
efflux transporters were found to significantly contribute
to each model, though BCRP and MRP1 expression was
most commonly implicated.
Discussion
This is the first study comprehensively comparing drug
transporter expression in the gastrointestinal tract across
animal models, and has demonstrated several novel
findings with important implications for drug develop-
ment and HIV eradication research. When gene and
protein expression data were pooled to investigate
differences between anatomic compartments and
between species, several important differences were
observed. The multiple log differences observed between
mice and macaques for ABCB1/MDR1 and ABCC4/
MRP4 indicate ART pharmacokinetic data generated in
one model may not easily be extrapolated to the other.
Given that several of these transporters have been shown
to efflux numerous antiretrovirals, the species used in
investigations of ART disposition into tissues, whether for
prevention or eradication, is a critically important
variable. RAL, for example, has been shown to reach
rectal concentrations that are 35-fold greater than plasma
in macaques [25]. We have also recently shown that RAL
distributes readily throughout the macaque rectum, but
that distribution in humanized mouse rectum is lacking
[26]. In this study, RAL NHP ileum and rectum
concentrations were increased over mice by 16 and
376-fold, respectively. Given that RAL is known to be
effluxed by MDR1, it may be the case that RAL
distributes into the intestinal mucosa in both species, but
is effluxed back into the intestinal lumen by MDR1 to a
greater extent in mice versus macaques, helping to
explain the decreased tissue concentrations in this model.
The distinct differences observed here provide support
that transporter expression may also differ between animal
models and humans.
Fig. 3. Multispecies comparison of transporter protein expression by quantitative targeted absolute proteomics. Absolute
protein concentrations are represented as pmol/mg protein for uninfected (white) and infected (gray) animals from multiple dosing
cohorts. Solid lines represent 1pmol/mg; dashed lines represent the lower limit of quantitation. Data shown are median and range;
() represents P< 0.05.
Not only does the current study provide important
information on transporter expression between animal
models, we also are the first to formally compare
methodologies for measuring transporter gene and
protein expression in tissues relevant for HIV research.
The extent of agreement between methods was generally
poor, with ABCG2/BCRP showing the only significant
relationship. There are several possible explanations for
this lack of correlation, including the fact that, compared
to the robust qPCR data, protein expression was highly
variable and was not observed in all samples. Conditions
for these experiments have been optimized by our
laboratory; however, lot-to-lot antibody variability and
lack of an accepted standard for quantifying densitometry
data are persistent challenges with the western blot
technique [27]. Further, mRNA inhibition by native
micro-RNAs or post-translational protein modifications
can affect the relationship between gene and protein
expression, and may be influencing the observed results.
Additionally, differential rates of mRNA degradation
between GAPDH and transporters may alter observed
expression despite correction for this housekeeping gene.
The lack of agreement between qPCR and western blot
data even after correction for GAPDH expression is
concerning, as there is currently no accepted standard in
the field for measurement of transporter expression.
Several groups have published data generated using both
methods [12,28]; however, the utility of western blot data
is limited due to narrow dynamic range and often possible
antibody cross reactivity. Further, relative gene expression
data should be interpreted with caution, as the high
sensitivity may lead to false positives. Using DNA
standards, we have determined that 8–10,000 copies of
Fig. 4. Lack of agreement between transporter evaluation methods. Correlation matrices are shown for the four efflux transporters
evaluated by all three methods.
GAPDH were present in each mouse sample, with 60–
100,000 GAPDH copies present in each NHP sample
(data not shown). Based on these values, relative
transporter expression values of 104 or greater represent
biologically plausible expression of these genes in our
samples; however, lower relative expression values may
simply mean that the gene is not expressed at all.
Proteomics analysis of the same tissues showed much
more robust data compared to those generated by western
blot in terms of overall frequency of detection (80% for
QTAP vs. 71% for western blot). However, even these
data showed little agreement when compared to qPCR
data. Despite the lack of agreement, QTAP tended to
agree with transporter localization data determined by
IHC, where MDR1 and BCRP were the most highly
expressed throughout the ileum and rectum, with
decreased expression of MRP1 and almost no expression
of MRP2. The ability of QTAP to provide robust,
downstream protein expression data with high sensitivity
and specificity for multiple transporters from a single
sample makes this an appealing technology. The lack of
agreement between QTAP and western blot is incon-
sistent with previous reports showing good correlation
between these methods [29]. However, those results have
been generated using recombinant enzymes, which do
not represent the complex biological tissue matrices
studied here. To the best of our knowledge, this is the first
study to compare these data using tissue homogenates.
Whereas this technology requires specialized equipment
and expertise, its use has become more widespread in
recent years [30–32].
Despite these advantages, the multivariable regression
analysis found that QTAP data did not provide a
significant increase in predicting observed TPR values
over data derived from other techniques (Table 1). These
results may be explained in part by the large amount of
undetectable samples for western blot and QTAP, which
may have reduced the ability to detect significant
relationships due to limited statistical power. Further,
the possibility of drug–drug interactions affecting tissue
ART exposure, particularly in the NHPs receiving EFV,
must be considered. In addition, we were limited by the
use of whole tissue homogenates to determine TPR.
Although this has been the current standard in the field,
TPR cannot distinguish between ART penetration
directly from the lumen versus penetration from
peripheral blood. Measuring ART concentrations from
luminal washes in addition to tissue concentrations can
highlight the effects of drug efflux and may have provided
a more discreet variable upon which to base our
regression model.
The negative results of this regression analysis may
indicate that drug transporters alone do not govern ART
Table 1. Multivariable regression analysis of drug transporter expression methods on TPR.
Drug Method MDR1 BCRP MRP2 MRP1 MRP4 R2
qPCR – – 0.01 – – 0.09
TFV WB – 0.01 – 0.05 – 0.38
QTAP – 0.01 – – – 0.11
IHC – – – – – n/a
qPCR – 0.007 – 0.008 – 0.41
FTC WB – 0.01 – 0.002 – 0.51
QTAP 0.04 – 0.05 – – 0.15
IHC – – – – – n/a
qPCR 0.56 0.002 – 0.002 – 0.43
RAL WB – 0.03 – 0.01 – 0.51
QTAP – – – 0.58 0.008 0.16
IHC – – – – – n/a
qPCR – 0.004 – 0.07 – 0.39
EFV WB – 0.12 – – – 0.22
QTAP – – – – – n/a
IHC – – – – – n/a
qPCR – – – – 0.06 0.17
ATZ WB – – – – – n/a
QTAP – – – – – n/a
IHC – – – – – n/a
qPCR – – – 0.002 – 0.23
MVC WB – – – – – n/a
QTAP – – – – – n/a
IHC – – – – – n/a
Forward stepwise regression was performed using TPR for each drug as the dependent variable, with plasma concentration and efflux transporter
expression as independent variables for the all methods used. Only the variables that were found to be significant in the univariate analysis were
included. P values for each independent variable are shown in the table, with statistically significant variables bolded. R2 values for each regression
model are shown on the far right. Models that did not identify any of the included variables as statistically significant in the univariate analysis do
not have R2 values and are shown as ‘n/a.’ ATZ, atazanavir; BCRP, breast cancer resistance protein; EFV, efavirenz; FTC, emtricitabine; IHC,
immunohistochemistry; MDR1, multidrug resistance protein; MRP1, multidrug resistance-associated proteins 1; MRP2, multidrug resistance-
associated proteins 2; MVC, maraviroc; qPCR, quantitative PCR; RAL, raltegravir; QTAP, quantitative targeted absolute proteomics; TFV, tenofovir;
WB, western blot.
tissue concentrations in a significant way, but must be
measured in the context of additional variables such as
drug metabolizing enzyme expression or drug pharma-
cokinetic properties, which were not examined here.
Understanding the contribution of drug metabolizing
enzymes would be of particular interest, as it has been
shown that the expression, regulation, and magnitude of
inhibition/induction can vary drastically between rodent
and nonrodent species [33]. Interspecies differences in
other factors such as target cell expression and the makeup
of intestinal microbiota are less well characterized, but
may have affected our results. Further, although these
humanized mouse models have shown success in
reconstituting systemic human lymphocyte populations,
it may be that these murine models do not fully
recapitulate the human gut microenvironment. It is
possible that consideration of these variables in tissue
accumulation would have improved the predictive ability
of the model. Given the high sensitivity and low
variability of qPCR data compared to other methods,
it is surprising that this method did not identify more
expected transporters; however, qPCR was able to
identify at least one significant variable for every drug.
The fact that gene expression is not always reflected by
protein expression could be seen as an issue with the
qPCR technique.
One of the most notable findings of this analysis is the
characterization of human drug transporter expression in
the tissues of both humanized mouse models. The extent
of peripheral immune humanization observed here was
consistent with previous studies using these models [34],
but this is the first study to quantify human transporter
expression in these animals. The detection of some
human transporter gene expression should not be
surprising given that many of these transporters are
expressed on the surface of human lymphocytes, which
are abundant in the humanized mouse gastrointestinal
tract, particularly in the ileum. We observed human gene
expression from nearly every transporter evaluated, and
found that ABCB1 and ABCC4 were expressed at an
extent equal to or greater than mouse transporters in
tissues from five mice (Supplementary Figure 4, http://
links.lww.com/QAD/B114). This implies some amount
of underestimation of the size of the total transporter
pool, and when human transporter isoforms were
accounted for (Appendix 3.8), ABCC4 results signifi-
cantly changed. However, ABCB1 results remained
consistent and the use of species-specific antibodies and
SILs for western blot and QTAP, respectively, preserved
the validity of our protein results. Future studies of drug
transporters and/or drug-metabolizing enzymes in these
mouse models should include the analysis of both mouse
and human-derived proteins.
Conclusion
As the body of evidence for persistent HIV replication
within tissue reservoirs continues to grow, so does the
need to define and quantify the factors influencing ART
disposition within these tissues. To that end, this analysis
compares drug transporter expression between com-
monly used animal models, and assesses the effect of
HIV infection on transporter expression. We also
demonstrate that the methods commonly used to evaluate
transporter expression have little agreement with each
other, and that robust downstream measures may have the
most utility. Finally, we are the first to quantify the
contribution of human transporters to the overall
transporter pool in the gastrointestinal tissue of these
humanized mouse models.
These data have important implications for future studies
of ART disposition in relation to HIV persistence. Our
finding that transporter expression methods are not in
agreement and that transporter data alone are insufficient
to predict ART tissue penetration highlights the need for
future studies on alternative endpoints. The contribution
of drug-metabolizing enzymes, physicochemical proper-
ties, and gut microbiota to the tissue and cellular
disposition of ART and their metabolites remains
undefined, but will be necessary to know and to inform
the development of future therapies targeted toward
HIV reservoirs.
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